<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25785" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neurofibromatosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Le</surname>
            <given-names>Cuong</given-names>
          </name>
          <aff>US Derm Partners</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bedocs</surname>
            <given-names>Paul M.</given-names>
          </name>
          <aff>Ohio University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Cuong Le declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Paul Bedocs declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25785.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neurofibromatosis is a neurocutaneous disorder characterized by tumors in the nervous system and skin. The most common types of neurofibromatosis are types 1 and 2, which are autosomal dominant. Neurofibromatosis type 1, also known as von Recklinghausen disease, presents with neurofibromas, cafe-au-lait spots, freckling, and optic gliomas. Bilateral vestibular schwannomas and meningiomas characterize neurofibromatosis type 2. Treatment for neurofibromatosis types 1 and 2 involves clinical monitoring and medical intervention when appropriate. This activity describes the pathophysiology, evaluation, and management of neurofibromatosis and highlights the role of the interprofessional team in caring for patients affected by this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of neurofibromatosis.</p></list-item><list-item><p>Evaluate&#x000a0;the presentation of a patient with neurofibromatosis.</p></list-item><list-item><p>Differentiate&#x000a0;the treatment and management options available for neurofibromatosis.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination to advance the treatment of neurofibromatosis and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25785&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25785">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25785.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Neurofibromatosis is a neurocutaneous disorder characterized by tumors in the nervous system and skin. Neurofibromatosis types 1 and 2 are the most common and are distinct entities (see <bold>Image.</bold> Neurofibromatosis, NF1,&#x000a0;NF2, and Schwannomatosis). Neurofibromatosis type 1, or von Recklinghausen disease, is an autosomal dominant.&#x000a0;Neurofibromatosis type 1&#x000a0;presents with neurofibromas, cafe-au-lait macules, freckling, and optic gliomas. It is a clinical diagnosis. Neurofibromatosis type 2 (NF2) is a disease characterized by bilateral vestibular schwannomas and meningiomas. It has an autosomal dominant inheritance pattern. Neurofibromatosis types 1 and 2 treatment is clinical monitoring and medical intervention when appropriate.<xref ref-type="bibr" rid="article-25785.r1">[1]</xref><xref ref-type="bibr" rid="article-25785.r2">[2]</xref><xref ref-type="bibr" rid="article-25785.r3">[3]</xref></p>
      </sec>
      <sec id="article-25785.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Neurofibromatosis type 1&#x000a0;is caused by a loss of function mutation, either de novo or inherited, on the neurofibromin&#x000a0;1 <italic toggle="yes">(NF1</italic>)&#x000a0;gene. It is located on band 17q11.2 and codes for neurofibromin. Neurofibromin is a tumor suppressor in the RAS/MAPK and mTOR pathways. Mosaicism can occur, resulting in the segmental, generalized, or gonadal&#x000a0;<italic toggle="yes">NF1</italic>&#x000a0;gene.&#x000a0;The segmental&#x000a0;<italic toggle="yes">NF1</italic>&#x000a0;gene has pigment changes, tumors, or both and is&#x000a0;limited to one or more body segments. The generalized&#x000a0;<italic toggle="yes">NF1</italic>&#x000a0;gene&#x000a0;appears similar to classic&#x000a0;<italic toggle="yes">NF1</italic>&#x000a0;but does not have the&#x000a0;<italic toggle="yes">NF1</italic>&#x000a0;gene mutation. Gonadal&#x000a0;<italic toggle="yes">NF1</italic>&#x000a0;gene&#x000a0;occurs when the mutation only affects the ova or sperm.&#x000a0;<italic toggle="yes">NF2</italic>&#x000a0;gene&#x000a0;is caused by a loss of function mutation of the&#x000a0;<italic toggle="yes">NF2</italic>&#x000a0;gene. It is located on band 22q12 and codes for merlin. Merlin is a cell membrane protein and a tumor suppressor that functions in the PI3kinase/Akt, Raf/MEK/ERK, and mTOR pathways.&#x000a0;<xref ref-type="bibr" rid="article-25785.r4">[4]</xref><xref ref-type="bibr" rid="article-25785.r5">[5]</xref></p>
      </sec>
      <sec id="article-25785.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Neurofibromatosis&#x000a0;type 1&#x000a0;makes up about 96% of all neurofibromatosis cases. Prevalence is 1 in 3000 births. It occurs equally between genders and races. Fifty percent of patients have a spontaneous mutation, and the other half have an inherited mutation. There is a 100% penetrance with variable expressivity.&#x000a0;Neurofibromatosis&#x000a0;type 2&#x000a0;makes up about 3% of all cases and has a prevalence between 1 in 33,000 births and 1 in 87,410. There is no gender or race predilection.&#x000a0;Neurofibromatosis&#x000a0;type 2&#x000a0;has variable presentations amongst different families. A more severe clinical presentation is associated with a frameshift or a nonsense mutation that results in a truncated protein.&#x000a0;<xref ref-type="bibr" rid="article-25785.r6">[6]</xref></p>
      </sec>
      <sec id="article-25785.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Neurofibromas are benign tumors with mixed cell types, including Schwann cells, perineural cells, and fibroblasts. The tumors also contain mast cells, axonal processes, and a collagenous extracellular matrix. Plexiform neurofibromas are similar to neurofibromas but arise from muscle nerve fascicles and can infiltrate the surrounding structures.&#x000a0;Schwannomas arise from the eighth cranial nerve. They comprise spindle cells with mixed Antoni A and Antoni B cellular arrangements, verocay bodies,&#x000a0;and hyalinised vessels.&#x000a0;<xref ref-type="bibr" rid="article-25785.r7">[7]</xref><xref ref-type="bibr" rid="article-25785.r8">[8]</xref></p>
      </sec>
      <sec id="article-25785.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Neurofibromatosis&#x000a0;type 1&#x000a0;has cutaneous and noncutaneous manifestations. Cafe-au-lait macules are one of the&#x000a0;7 diagnostic criteria for neurofibromatosis&#x000a0;type 1. The lesions are sharply demarcated with a homogenous appearance. Axillary and groin freckling, or Crowe sign is the most specific criteria for neurofibromatosis&#x000a0;type 1. Neurofibromas can occur anywhere on the body. They can be cutaneous or internal. Dermal tumors are soft dome-shaped tumors but can also present as pedunculated, nodular, or plaque-like. Internal tumors are deeper and can occur around the eye, retroperitoneal, along with the gastrointestinal tract, or in the mediastinum. Neurofibromas have a buttonhole sign. Plexiform neurofibromas are usually present from birth and are derived from the nerve sheaths (see <bold>Image.</bold> Solitary Giant Neurofibroma). They can feel like a "bag of worms." Cutaneous manifestations include scoliosis, long bone dysplasia, learning difficulties, and attention deficit hyperactivity disorder. Lisch nodules are hyperpigmentation in the iris. They do not affect vision. Optic glioma is a tumor of the optic nerve and can affect vision. It occurs in 15% of patients with neurofibromatosis&#x000a0;type 1. Patients also have generalized hyperpigmentation, blue-red, pseudoatrophic macules, juvenile xanthogranuloma, glomus tumor, melanoma, nevus anemicus, and pruritus. Patients are at increased risk for rhabdomyosarcoma, myeloid leukemia, and pheochromocytomas.</p>
        <p>Neurofibromatosis&#x000a0;type 2&#x000a0;patients present most commonly with schwannomas and meningiomas (see <bold>Image.</bold> Neurofibromatosis). Bilateral&#x000a0;vestibular&#x000a0;schwannoma&#x000a0;and unilateral&#x000a0;vestibular&#x000a0;schwannoma&#x000a0;occur on the superior division of the eighth cranial nerve. This is the most common type but can occur with any cranial nerve. Involvement of the facial nerve with the&#x000a0;vestibular&#x000a0;schwannoma&#x000a0;can make surgical treatment difficult. These patients present with tinnitus, hearing loss, and difficulty with balance. Patients that have the truncated protein were found to have the disease of onset at a younger age and a higher prevalence of tumors. Younger patients also have an earlier onset of symptoms.<xref ref-type="bibr" rid="article-25785.r9">[9]</xref></p>
      </sec>
      <sec id="article-25785.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The NIH has&#x000a0;7 diagnostic criteria for neurofibromatosis&#x000a0;type 1. Two must be met for the diagnosis. Genetic testing is not routinely done.&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Six&#x000a0;or more cafe-au-lait spots greater than 5 mm prepubertal and greater than 15 mm post-pubertal</p>
          </list-item>
          <list-item>
            <p>Two&#x000a0;or more neurofibromas or one or more plexiform neurofibroma</p>
          </list-item>
          <list-item>
            <p>Axillary or groin freckling</p>
          </list-item>
          <list-item>
            <p>Optic glioma</p>
          </list-item>
          <list-item>
            <p>Two or more Lisch nodules</p>
          </list-item>
          <list-item>
            <p>Sphenoid dysplasia, dysplasia or thinning of long bone cortex</p>
          </list-item>
          <list-item>
            <p>First-degree relative with&#x000a0;neurofibromatosis&#x000a0;type 1</p>
          </list-item>
        </list>
        <p>Differential diagnosis includes&#x000a0;neurofibromatosis&#x000a0;type 1-like syndrome, familial cafe-au-lait spots, and segmental&#x000a0;neurofibromatosis&#x000a0;type 1. The nf1-like syndrome was first described in 2007. Patients with the&#x000a0;neurofibromatosis&#x000a0;type 1-like syndrome have cafe-au-lait spots, axillary freckling, and macrocephaly, but they lack the <italic toggle="yes">NF1</italic> genetic mutation, neurofibromas, and Lisch nodules. It is an autosomal dominant disease due to a mutation in the&#x000a0;<italic toggle="yes">SPRED1</italic>&#x000a0;gene on chromosome 15. Familial cafe-au-lait spots are a disorder presenting only cafe-au-lait macules.</p>
        <p>Bilateral vestibular&#x000a0;schwannoma is pathognomic for&#x000a0;neurofibromatosis&#x000a0;type 2, but not all patients with this condition have bilateral schwannoma. The NIH has diagnostic criteria for neurofibromatosis&#x000a0;type 2.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Definitive Neurofibromatosis Type 2: Bilateral&#x000a0;vestibular&#x000a0;schwannoma&#x000a0;or a first-degree relative with&#x000a0;neurofibromatosis&#x000a0;type 2&#x000a0;plus unilateral&#x000a0;vestibular&#x000a0;schwannoma&#x000a0;in someone less than 30 or any&#x000a0;2 of the following: meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacities/juvenile cortical cataract</p>
          </list-item>
          <list-item>
            <p>Presumptive or Probable Neurofibromatosis Type 2: Unilateral&#x000a0;vestibular&#x000a0;schwannoma&#x000a0;in someone under 30 plus one of the following: meningioma,&#x000a0;schwannoma,&#x000a0;glioma, juvenile posterior subcapsular lenticular opacities/juvenile cortical cataract. Multiple meningiomas (2 or greater) plus unilateral&#x000a0;vestibular&#x000a0;schwannoma&#x000a0;less than 30 years or one of the following: schwannoma glioma, juvenile posterior subcapsular lenticular opacities/juvenile cortical cataract&#x000a0;<xref ref-type="bibr" rid="article-25785.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25785.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Cafe-au-lait spots and neurofibromas are benign and do not require treatment. Surgical excision can be performed on symptomatic lesions, but recurrence can occur. Plexiform neurofibromas have malignant potential. There is an 8% to 13% risk for plexiform neurofibromas to develop into malignant peripheral nerve sheath tumors. This should be suspected if there is pain for more than&#x000a0;one month, new neurologic deficits, change of the neurofibroma from soft to hard, or a rapid increase in size. These malignancies are treated with wide local excision. Imatinib has been shown to decrease plexiform neurofibroma size.</p>
        <p>Monitoring for any neurologic changes and referral to a neurologist is paramount. These changes can be due to tumor development. Consistent ophthalmologic evaluation is recommended for observation of the development of optic gliomas. Chemotherapy is the treatment of choice for optic gliomas. It is important to monitor children for difficulty learning and behavioral issues. Counseling can be beneficial for patients to provide support regarding the disease's autosomal dominant inheritance pattern.</p>
        <p>Patients with neurofibromatosis&#x000a0;type 2 require the assessment of their hearing. Ophthalmology evaluation, MRI, audiology, and brainstem evoked potentials are important in managing these patients. Surgery is still the first-line treatment for symptomatic tumors, but there is a 44% recurrence rate. Radiation can be used, but there is an increased risk of malignant transformation. Bevacizumab,&#x000a0;a VEGF inhibitor, is a monoclonal antibody that can medically treat neurofibromatosis type 2 patients. It decreased tumor size in 53% of cases and improved hearing in 57%. Patients with suspected&#x000a0;neurofibromatosis&#x000a0;type 2&#x000a0;should have an MRI of the head and spine done. Getting thin cuts through the internal auditory canals is important. Treatment is done if the tumor is compressing the brainstem or preventing hearing loss.&#x000a0;<xref ref-type="bibr" rid="article-25785.r11">[11]</xref><xref ref-type="bibr" rid="article-25785.r12">[12]</xref><xref ref-type="bibr" rid="article-25785.r13">[13]</xref></p>
      </sec>
      <sec id="article-25785.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis for neurofibromatosis include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acoustic neuroma</p>
          </list-item>
          <list-item>
            <p>Brainstem syndromes</p>
          </list-item>
          <list-item>
            <p>Caf&#x000e9;-au-lait spots</p>
          </list-item>
          <list-item>
            <p>Legius syndrome (SPRED1 -related caf&#x000e9;-au-lait spots and freckles)</p>
          </list-item>
          <list-item>
            <p>McCune-Albright syndrome</p>
          </list-item>
          <list-item>
            <p>Spinal injury</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25785.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of neurofibromatosis is best done with an interprofessional team, including dermatologists, neurologists, pediatricians, and genetic counselors. The key is to monitor the patient for CNS tumors, which, if detected late, have a poor prognosis. Genetic counseling should be available to patients with an affected child. The dermatologist, ophthalmologist, neurosurgeon, neurologist, and general surgeon should regularly follow up with these patients to ensure that no mass lesions are developing in the body.</p>
      </sec>
      <sec id="article-25785.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25785&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25785">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/neurofibromatosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25785">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25785/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25785">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25785.s12">
        <fig id="article-25785.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Neurofibromatosis, NF1, NF2, and Schwannomatosis. Neurofibromatosis encompasses three distinct disorders: neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis.&#x000a0; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="neurofibromatosis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25785.s13">
        <fig id="article-25785.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Neurofibromatosis Contributed by S Verma, MBBS, DVD, FRCP, FAAD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Neurofibromatosis__SV1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25785.s14">
        <fig id="article-25785.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Solitary Giant Neurofibroma Contributed by S Munakomi, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NEUROFIBROMA" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25785.s15">
        <title>References</title>
        <ref id="article-25785.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyd</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Korf</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Theos</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neurofibromatosis type 1.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-14; quiz 15-6</page-range>
            <pub-id pub-id-type="pmid">19539839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghalayani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saberi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sardari</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Neurofibromatosis type I (von Recklinghausen's disease): A family case report and literature review.</article-title>
            <source>Dent Res J (Isfahan)</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>483</fpage>
            <page-range>483-8</page-range>
            <pub-id pub-id-type="pmid">23162593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asthagiri</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Butman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Tsilou</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lonser</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Neurofibromatosis type 2.</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>Jun</month>
            <day>06</day>
            <volume>373</volume>
            <issue>9679</issue>
            <fpage>1974</fpage>
            <page-range>1974-86</page-range>
            <pub-id pub-id-type="pmid">19476995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jouhilahti</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Peltonen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heape</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Peltonen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The pathoetiology of neurofibromatosis 1.</article-title>
            <source>Am J Pathol</source>
            <year>2011</year>
            <month>May</month>
            <volume>178</volume>
            <issue>5</issue>
            <fpage>1932</fpage>
            <page-range>1932-9</page-range>
            <pub-id pub-id-type="pmid">21457932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Neurofibromatosis type 2 (NF2): a clinical and molecular review.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2009</year>
            <month>Jun</month>
            <day>19</day>
            <volume>4</volume>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">19545378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slattery</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Neurofibromatosis type 2.</article-title>
            <source>Otolaryngol Clin North Am</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>443</fpage>
            <page-range>443-60</page-range>
            <pub-id pub-id-type="pmid">26043141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kresak</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis.</article-title>
            <source>J Pediatr Genet</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>98</fpage>
            <page-range>98-104</page-range>
            <pub-id pub-id-type="pmid">27617150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jouhilahti</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Peltonen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Callens</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jokinen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Heape</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Messiaen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Peltonen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The development of cutaneous neurofibromas.</article-title>
            <source>Am J Pathol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>178</volume>
            <issue>2</issue>
            <fpage>500</fpage>
            <page-range>500-5</page-range>
            <pub-id pub-id-type="pmid">21281783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ullrich</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Neurocutaneous Syndromes and Brain Tumors.</article-title>
            <source>J Child Neurol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>1399</fpage>
            <page-range>1399-411</page-range>
            <pub-id pub-id-type="pmid">26459515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goutagny</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kalamarides</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.</article-title>
            <source>Neurochirurgie</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>64</volume>
            <issue>5</issue>
            <fpage>370</fpage>
            <page-range>370-374</page-range>
            <pub-id pub-id-type="pmid">28162254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferner</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Huson</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Willshaw</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Upadhyaya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Towers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gleeson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steiger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the diagnosis and management of individuals with neurofibromatosis 1.</article-title>
            <source>J Med Genet</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-8</page-range>
            <pub-id pub-id-type="pmid">17105749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robertson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Nalepa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Bowers</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Hutchins</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Croop</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Vik</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Denne</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Parada</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Hingtgen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pradhan</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Edwards-Brown</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Travers</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Staser</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Ingram</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Clapp</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>1218</fpage>
            <page-range>1218-24</page-range>
            <pub-id pub-id-type="pmid">23099009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25785.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirbe</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gutmann</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Neurofibromatosis type 1: a multidisciplinary approach to care.</article-title>
            <source>Lancet Neurol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>834</fpage>
            <page-range>834-43</page-range>
            <pub-id pub-id-type="pmid">25030515</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
